FDA Approves Mitomycin Intravesical Solution for Recurrent Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

On June 12, the FDA approved mitomycin intravesical solution for adult patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer.

For more information, read the FDA announcement and visit the UroGen Pharma website.

Posted on 6/12/2025